CYB210010 (Cybin Inc.)

CYB210010 is a potent, orally bioavailable, and long-acting small molecule serotonin 5-HT2 receptor agonist developed by Cybin. It is the lead candidate within the CYB005 phenethylamine program, which focuses on a novel class of 2,5-dimethoxy-4-thiofluoroalkyl phenethylamines. CYB210010 acts as a potent agonist at 5-HT2A and 5-HT2C receptors, with modest selectivity over 5-HT2B and 5-HT1A receptors. Preclinical data indicates that the compound readily crosses the blood-brain barrier, engages frontal cortex 5-HT2A receptors, and increases the expression of genes associated with neuroplasticity. Cybin is exploring the therapeutic potential of CYB210010 and related molecules for central nervous system (CNS) disorders, including neuroinflammation and psychiatric conditions, with a focus on both psychedelic and non-hallucinogenic dosing regimens.

Other names

2,5-dimethoxy-4-thiofluoroalkyl phenethylamines2,5-dimethoxy-4-thiotrifluoromethylphenethylamines